Onconova Therapeutics Inc Share Price Nasdaq
Equities
US68232V3069
Biotechnology & Medical Research
Sales 2024 * | 210K 16.67M | Sales 2025 * | 300K 23.81M | Capitalization | 13.71M 1.09B |
---|---|---|---|---|---|
Net income 2024 * | -23M -1.83B | Net income 2025 * | -28M -2.22B | EV / Sales 2024 * | 65.3 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 45.7 x |
P/E ratio 2024 * |
-0.75
x | P/E ratio 2025 * |
-0.78
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.39% |
Latest transcript on Onconova Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Steven Fruchtman
PSD | President | 73 | 18/01/15 |
Mark Guerin
DFI | Director of Finance/CFO | 55 | 31/08/13 |
Meena Arora
CTO | Chief Tech/Sci/R&D Officer | - | 23/10/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Marino
BRD | Director/Board Member | 74 | 30/06/15 |
Jack Stover
BRD | Director/Board Member | 69 | 22/05/16 |
Mary Shoemaker
BRD | Director/Board Member | 63 | 31/03/20 |
1st Jan change | Capi. | |
---|---|---|
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+47.13% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |